CE Disclosures and Faculty Information

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lung cancer.
  
  LEARNING OBJECTIVES

  • Identify common adverse events associated with EGFR tyrosine kinase inhibitors alone or in combination with other systemic approaches for metastatic non-small cell lung cancer (NSCLC) with an EGFR tumor mutation, and appropriately apply this information in patient care.
  • Consider the recent FDA approval of adjuvant osimertinib for early-stage NSCLC with EGFR mutation, and identify patients for whom treatment with this agent might be beneficial.
  • Appreciate available clinical trial findings supporting the recent FDA approval of lorlatinib for patients with metastatic NSCLC with ALK rearrangements, and discern how this agent can be optimally employed in nonresearch clinical practice.
  • Assess the efficacy of commercially available EGFR tyrosine kinase inhibitors for patients with metastatic NSCLC with EGFR mutations, and apply this understanding to the selection and sequencing of these drugs as first- and later-line therapy.
  • Recall other oncogenic pathways (ie, ROS1, RET, HER2, KRAS) mediating the pathogenesis of tumors in unique patient subgroups, and employ available and recently FDA-approved agents in the care of those individuals.
  • Recognize treatment options for patients with NSCLC and targetable mutations who develop brain metastases.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Professor Solange Peters, MD, PhD
  Head, Medical Oncology
  Chair, Thoracic Malignancies
  Oncology Department
  Lausanne University Hospital (CHUV)
  Lausanne, Switzerland
  
  Advisory Committee and Consulting Agreements (All fees to institution): AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biocartis, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Daiichi Sankyo Inc, Debiopharm Group, Elsevier, Foundation Medicine, Genentech, a member of the Roche Group, Illumina, Incyte Corporation, IQVIA, Janssen Biotech Inc, Lilly, Merck Serono, Merck Sharp & Dohme Corp, Merrimack Pharmaceuticals Inc, Novartis, Pfizer Inc, PharmaMar, Phosplatin Therapeutics, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Takeda Oncology; Data and Safety Monitoring Board/Committee: Lilly; Speaking Engagements (All fees to institution): AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Lilly, Merck Sharp & Dohme Corp, Pfizer Inc, Sanofi Genzyme, Takeda Oncology.
  
  Zofia Piotrowska, MD, MHS
  Assistant Professor of Medicine
  Harvard Medical School
  Massachusetts General Hospital
  Boston, Massachusetts
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, C4 Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medtronic Inc, Takeda Oncology; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Cullinan Oncology, Daiichi Sankyo Inc, Janssen Biotech Inc, Novartis, Spectrum Pharmaceuticals Inc, Takeda Oncology, Tesaro, A GSK Company.
  
  Gregory J Riely, MD, PhD
  Associate Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Advisory Committee (Uncompensated): Daiichi Sankyo Inc, Mirati Therapeutics, Pfizer Inc; Contracted Research: Merck, Mirati Therapeutics, Novartis, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc and Turning Point Therapeutics Inc.
  
  Release date: September 2021
  Expiration date: September 2022